Updates in COPD: 25-Slide PowerPoint Presentation
Slide 1: Title Slide
Recent Updates in Chronic Obstructive Pulmonary Disease (COPD) Evidence-Based Advances in Diagnosis and Management
Slide 2: The Paradigm Shift in COPD Management
COPD management has fundamentally transformed from empirical bronchodilation to precision medicine based on treatable traits 1, 2. The 2024-2026 period marks a historic inflection point with three mechanistically distinct agents receiving FDA approval—the first substantive pharmacological innovation in over two decades 1.
Key transition:
- From: One-size-fits-all bronchodilator approach
- To: Biomarker-driven, pathobiology-aligned precision treatment
Slide 3: Updated Risk Stratification Framework
The 2023 Canadian Thoracic Society guideline provides clear exacerbation risk definitions 3:
Low Risk:
- ≤1 moderate exacerbation in past year
- No hospital admission/ED visit
High Risk:
- ≥2 moderate exacerbations OR
- ≥1 severe exacerbation (hospitalization/ED visit) in past year
This stratification drives all subsequent treatment decisions.
Slide 4: Symptom Assessment Tools
Use validated instruments to quantify symptom burden 3:
- CAT (COPD Assessment Test): Simple, validated tool
- Score <10: Low symptom burden
- Score ≥10: Moderate to high symptoms
- mMRC (Modified Medical Research Council): Dyspnea grading
- Score ≥2: Significant breathlessness
These scores directly determine initial therapy selection.
Slide 5: Initial Treatment Algorithm - Low Symptoms, Low Risk
For patients with CAT <10 and FEV₁ ≥80% predicted 3:
Start with single long-acting bronchodilator (LABD):
- Either LAMA or LABA
- Choice based on availability and patient response
- Add short-acting bronchodilator (SABD) as needed
This represents the minimal effective therapy for mild disease.
Slide 6: Initial Treatment - Moderate to High Symptoms
For patients with mMRC ≥2, CAT ≥10, and FEV₁ <80% predicted 3:
LAMA/LABA dual therapy is the recommended initial maintenance treatment.
Critical point: LAMA/LABA is preferred over ICS/LABA due to:
Exception: Use ICS/LABA only if concomitant asthma is present 3.
Slide 7: Triple Therapy Indications
LAMA/LABA/ICS triple combination therapy is recommended for symptomatic patients at high risk of exacerbations 3.
Preferably administered as single-inhaler triple therapy (SITT) rather than multiple inhalers 3.
Triple therapy improves:
- Lung function
- Symptoms and health status
- Reduces exacerbations compared to dual therapy 4
Slide 8: The ICS Controversy - When to Use
ICS use requires careful patient selection due to significant risks 4:
Use ICS when:
- High exacerbation risk despite LABA/LAMA
- Concomitant asthma
- Elevated blood eosinophil counts (see biomarker section)
ICS increases risk of:
- Pneumonia (especially in severe disease)
- Oral candidiasis
- Skin bruising
- Possible diabetes/cataracts/mycobacterial infection 4
Slide 9: ICS Withdrawal Considerations
Weak recommendation to continue triple therapy rather than stepping down to LAMA/LABA in patients with 3:
- CAT ≥10 AND/OR
- FEV₁ <80% predicted
However, ICS withdrawal may be appropriate when:
- Recurrent pneumonia occurs
- No exacerbation benefit observed
- Low eosinophil counts
Evidence on withdrawal remains equivocal 4.
Slide 10: Blood Eosinophils - The Key Biomarker
Blood eosinophil count (BEC) enables precision medicine in COPD 2, 5.
Higher BEC predicts:
- Greater response to ICS therapy
- Better response to biologic agents targeting type 2 inflammation
- Exacerbations may be more steroid-responsive 4
Clinical application: Use BEC to guide ICS initiation and biologic therapy selection 2.
Slide 11: Novel Biologics - Dupilumab
Dupilumab (anti-IL-4/IL-13) represents breakthrough therapy for eosinophilic COPD phenotypes 1, 2, 5.
Demonstrated efficacy:
- Significant exacerbation reduction in eosinophil-enriched populations
- Improved lung function
- First biologic to show substantial benefit in COPD
Target population: Patients with elevated eosinophils and persistent exacerbations despite optimal inhaled therapy.
Slide 12: Other Emerging Biologics
Additional biologic targets showing promise 1, 5:
Anti-IL-5 pathway (Mepolizumab):
- Targets eosinophilic inflammation
- Reduces exacerbations in selected patients
Upstream alarmin antagonists:
- Anti-IL-33
- Anti-TSLP (thymic stromal lymphopoietin)
These agents shift treatment from widespread inflammation to precise molecular targets.
Slide 13: Ensifentrine - Novel Dual PDE Inhibitor
Ensifentrine represents the first novel inhaled small molecule in decades 1, 2.
Mechanism: Dual phosphodiesterase-3/4 inhibition
Advantages over oral roflumilast:
- Inhaled delivery reduces systemic side effects
- Combines bronchodilation with anti-inflammatory effects
This addresses a critical gap in COPD pharmacotherapy.
Slide 14: Oral Adjunctive Therapies - Roflumilast
PDE-4 inhibitor for specific patient populations 4:
Indications:
- FEV₁ <50% predicted
- Chronic bronchitis phenotype
- ≥1 hospitalization for exacerbation in previous year
- Already on LABA/LAMA/ICS with persistent exacerbations
Mechanism: Reduces moderate and severe exacerbations 4.
Limitation: Gastrointestinal side effects common.
Slide 15: Macrolide Therapy
Long-term azithromycin or erythromycin reduces exacerbations over one year 4.
Specific indication:
- Former smokers (not current smokers)
- Persistent exacerbations despite optimal inhaled therapy
- Chronic bronchitis phenotype 4
Critical caveat: Associated with bacterial resistance development and hearing impairment 4. Weigh benefits against antimicrobial stewardship concerns.
Slide 16: Mucolytic Agents
N-acetylcysteine (NAC) and carbocysteine reduce exacerbation risk in select populations 4.
Target patients:
- Chronic bronchitis with frequent exacerbations
- Not recommended for all COPD patients
Evidence level: Moderate (Evidence B) 4.
Antioxidant mucolytics recommended only in selected patients, not as universal therapy.
Slide 17: What NOT to Use
Strong recommendations against certain therapies 3, 4:
Do NOT use:
- ICS monotherapy in stable COPD with low exacerbation risk 3
- Long-term oral corticosteroids (no benefit, multiple complications) 4
- Methylxanthines for exacerbations (side effects outweigh benefits) 4
- Statins for exacerbation prevention (no benefit in dedicated trials) 4
Slide 18: Smoking Cessation - Still Paramount
Smoking cessation remains the only intervention that modifies long-term lung function decline 4.
Effective strategies:
- Pharmacotherapy: Varenicline, bupropion, nortriptyline (increase quit rates) 4
- Nicotine replacement: More effective than placebo 4
- Counseling: Professional support significantly increases success 4
- Combination: Pharmacotherapy + behavioral support = highest success 4
E-cigarettes: Efficacy as cessation aid remains controversial 4.
Slide 19: Vaccination Strategies
Vaccinations decrease lower respiratory tract infections 4:
Influenza vaccination:
- Reduces serious illness, death, and exacerbations 4
- Decreases ischemic heart disease risk 4
- Use killed or live inactivated viruses 4
Pneumococcal vaccination:
- PCV13 and PPSV23 recommended for all patients ≥65 years 4
These are evidence-based, cost-effective interventions.
Slide 20: Pulmonary Rehabilitation
Pulmonary rehabilitation improves symptoms, quality of life, and physical/emotional participation in daily activities 4.
Target patients:
- High symptom burden (Groups B, C, D)
- High exacerbation risk
- Consider individual characteristics and comorbidities 4
Components:
- Combination of aerobic and strength training most effective 4
- Tiotropium improves rehabilitation effectiveness 4
Slide 21: Exacerbation Management - Acute Treatment
Key principles for acute exacerbations 4:
Bronchodilators:
- Short-acting β₂-agonists ± short-acting anticholinergics as initial therapy 4
- Initiate long-acting bronchodilators before hospital discharge 4
Systemic corticosteroids:
- Improve FEV₁, oxygenation, recovery time, and hospitalization duration 4
Antibiotics:
- When indicated (purulent sputum), shorten recovery and reduce relapse 4
Slide 22: Exacerbation Classification and Risk
Exacerbations classified by severity 4:
- Mild: Treated with short-acting bronchodilators only
- Moderate: Requires antibiotics and/or oral corticosteroids
- Severe: Hospitalization or ED visit required
Frequent exacerbators (≥2 per year):
- Worse health status and morbidity 4
- Require escalation to triple therapy or adjunctive agents
- 20% not recovered at 8 weeks 4
Slide 23: Long-Term Oxygen and Ventilation
Oxygen therapy indications 4:
Long-term oxygen improves survival in:
- Severe resting chronic hypoxemia
Do NOT routinely prescribe for:
- Stable COPD with resting or exercise-induced moderate desaturation 4
Long-term noninvasive ventilation:
- May decrease mortality in severe chronic hypercapnia with history of acute respiratory failure hospitalization 4
Slide 24: The Treatable Traits Framework
COPD management shifts from categorical diagnosis to identification of specific, modifiable pathobiological characteristics 1:
Key treatable traits:
- Eosinophilic inflammation → ICS, biologics
- Frequent exacerbations → Triple therapy, macrolides, PDE-4 inhibitors
- Chronic bronchitis → Mucolytics, roflumilast
- Smoking → Cessation interventions
- Deconditioning → Pulmonary rehabilitation
This framework enables truly personalized medicine.
Slide 25: Future Directions and Emerging Technologies
COPD therapeutics at the threshold of disease modification 1, 5:
Emerging approaches:
- Gene editing technologies
- Senolytic therapy (targeting cellular senescence)
- Advanced biomarker panels for phenotyping
- Artificial intelligence-assisted CT analysis for early detection 5
- Multi-tiered screening systems based on healthcare resource stratification 5
The convergence of biologics, small molecules, and emerging technologies positions COPD management for transformative change 1.